Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. AVO.L Share Price
  4. AVO.L Share Regulatory News
  5. Director Dealing

Pin to quick picksAVO.L Regulatory News (AVO)

AVO.L Information
  • There is currently no data for AVO

Director Dealing

26 Apr 2013 07:00

RNS Number : 2913D
Advanced Oncotherapy PLC
26 April 2013
 

26 April 2013

 

ADVANCED ONCOTHERAPY Plc

("Advanced Oncotherapy" or "the Company")

 

Director Dealing

 

Advanced Oncotherapy (AIM: AVO) announces that on 25 April 2013, Michael Sinclair, Chief Executive Officer, purchased 8,250,000 ordinary shares of 1 pence each in the share capital of the Company ("Ordinary Shares") at an average price of 1.655 pence per share.

 

Following this purchase, Michael Sinclair now holds 69,355,121 Ordinary Shares, representing approximately 26.7 per cent. of the issued share capital of Advanced Oncotherapy.

 

For further information, please visit www.advancedoncotherapy.comor contact:

 

Michael Sinclair,

Chief Executive

Sandy Jamieson

Jon Levinson

Simon Hudson

Advanced

Oncotherapy Plc

Libertas Capital

Corporate Finance Ltd

Peterhouse

Corporate Finance

Tavistock Communications

(NOMAD & Joint Broker)

(Joint Broker)

(Financial PR & IR)

+44 20 3617 8739

+44 20 7569 9650

+44 20 7469 0930

+44 20 7920 3150

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBIGDSDDDBGXU
12345678910
Date   Source Headline
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility
1st Mar 20232:54 pmRNSSecured Convertible Note Facility & other matters
1st Mar 20232:05 pmRNSSecond Price Monitoring Extn
1st Mar 20232:00 pmRNSPrice Monitoring Extension
27th Jan 20234:53 pmEQSHardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to date
18th Jan 20232:00 pmRNSOperational update
17th Jan 20233:10 pmEQSHardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV
30th Dec 20221:00 pmRNSTotal Voting Rights
30th Dec 20229:24 amRNSDirector/PDMR Shareholding
29th Dec 20223:12 pmRNSDirector/PDMR Shareholding
28th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 202212:40 pmRNSSecond Price Monitoring Extn
23rd Dec 202212:35 pmRNSPrice Monitoring Extension
12th Dec 20227:00 amRNSEquity Subscription and Issue of Warrants
1st Dec 20227:00 amRNSIssue of Equity
28th Nov 20227:00 amRNSStudy showcases the potential superiority of LIGHT
3rd Nov 20223:20 pmRNSInvestor / Analyst Event Update
31st Oct 20225:00 pmRNSTotal Voting Rights
27th Oct 20227:31 amRNSPresentation highlights superiority of LIGHT
21st Oct 20227:00 amRNSNotice of Investor / Analyst Event
18th Oct 20227:00 amRNSEquity Subscription and Issue of Warrants
30th Sep 20225:00 pmRNSTotal Voting Rights
30th Sep 20227:00 amRNSInterim Results
29th Sep 20227:15 amEQSHardman & Co Research on Advanced Oncotherapy: Major milestone achieved
27th Sep 202210:30 amRNSLIGHT accelerator fully operational
31st Aug 20225:00 pmRNSTotal Voting Rights
23rd Aug 20223:09 pmRNSUpdate re admission of Subscription Shares
19th Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
17th Aug 20225:30 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
29th Jul 20224:30 pmRNSResult of AGM
7th Jul 202212:30 pmRNSHolding(s) in Company
30th Jun 20225:00 pmRNSTotal Voting Rights
30th Jun 20229:00 amRNSFinal results for the year ended 31 December 2021
28th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
13th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
31st May 20225:00 pmRNSTotal Voting Rights
27th May 202212:17 pmRNSHolding(s) in Company
11th May 20227:00 amRNSLIGHT system potential in delivering FLASH
29th Apr 20225:00 pmRNSTotal Voting Rights
27th Apr 20227:00 amRNSVideo showcases progress on LIGHT system process
26th Apr 20227:00 amRNSOperational update
22nd Apr 20227:00 amRNSUpdate re admission of Subscription Shares
19th Apr 20224:05 pmRNSUpdate re admission of Subscription Shares
12th Apr 20227:13 amRNSEquity Subscription and Issue of Warrants
31st Mar 20225:00 pmRNSTotal Voting Rights
25th Mar 20229:30 amRNS£2m Subscription, Add'l Loan and Issue of Warrants
14th Mar 20227:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO) - LIGHT: regulatory update
4th Mar 20229:00 amRNSDirector/PDMR Notification
3rd Mar 20226:13 pmRNSHolding(s) in Company
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
LOGP
Lansdowne Oil
LSE
0.00%
AA.
AA..L
LSE
0.00%
HPAC
HPAC.L
LSE
0.00%
JMG
JPMorgan Emerging Markets Investment Trust
LSE
0.00%
JPSS
Jpmor. Jap.smls
LSE
0.00%
Trending
RCGH
Rc365 Holding
LSE
102.86%
ITM
Itm Power
LSE
-8.07%
GGP
Greatland Resources
LSE
-3.22%
GST
GSTechnologies
LSE
0.00%
OMI
Orosur Mining
LSE
3.54%